Addison Capital Co lifted its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 11.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,630 shares of the financial services provider’s stock after purchasing an additional 164 shares during the quarter. Addison Capital Co’s holdings in iShares Biotechnology ETF were worth $237,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in IBB. Blue Fin Capital Inc. grew its position in iShares Biotechnology ETF by 0.7% in the second quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after acquiring an additional 74 shares during the period. Security National Bank of SO Dak grew its position in iShares Biotechnology ETF by 0.7% in the second quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after acquiring an additional 75 shares during the period. SPC Financial Inc. grew its position in iShares Biotechnology ETF by 2.4% in the third quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock worth $475,000 after acquiring an additional 75 shares during the period. Main Street Financial Solutions LLC grew its position in iShares Biotechnology ETF by 1.0% in the second quarter. Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock worth $1,098,000 after acquiring an additional 82 shares during the period. Finally, Perkins Coie Trust Co grew its position in iShares Biotechnology ETF by 0.3% in the second quarter. Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock worth $3,457,000 after acquiring an additional 83 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Down 0.5 %
Shares of iShares Biotechnology ETF stock opened at $145.69 on Friday. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $150.57. The stock has a 50 day moving average of $145.57 and a 200 day moving average of $139.59.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Election Stocks: How Elections Affect the Stock Market
- Global Lithium Demand Soars: Top 3 Stocks Positioned to Gain
- Stock Market Sectors: What Are They and How Many Are There?
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- Industrial Products Stocks Investing
- AI Boom Fuels Demand for Dominion Energy Stock
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.